Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

South Korean teens drive up COVID-19 cases ahead of full school reopening

Published 11/03/2021, 01:17 AM
Updated 11/03/2021, 05:18 AM
© Reuters. FILE PHOTO: A man who got a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine leaves a COVID-19 vaccination center in Seoul, South Korea, October 29, 2021.    REUTERS/Kim Hong-Ji

By Sangmi Cha

SEOUL (Reuters) - South Korea said on Wednesday it would ramp up COVID-19 testing at schools after a sharp rise of infections among children, weeks ahead of a plan to fully reopen schools nationwide.

The surge comes as new social distancing rules aimed at a phased return to normal came into effect on Monday as a part of the country's plan to gradually move toward living with COVID-19 on the back of high vaccination rates.

South Korea has fully vaccinated nearly 90% of its adult population but only began inoculating children aged between 12 and 17 in recent weeks, administering just 0.6% of the age group with both doses so far.

"There is a growing concern as the frequency of new cluster outbreaks has been increasing, centred on educational facilities such as private tuition centres and schools," Interior and Safety Minister Jeon Hae-cheol said.

The government would expand the use of portable polymerase chain reaction (PCR) diagnostic tests for COVID-19 in schools in Seoul and neighbouring regions, and mobilise more virus-prevention personnel in overcrowded schools, he said.

South Korea plans to fully reopen schools nationwide from Nov. 22.

The country reported 2,667 new cases for Tuesday, an increase of more than 1,000 from the day earlier. Nearly one-fourth of the new cases were found in teenagers, officials said.

"The teenagers spend a lot of time in communal living such as schools and tuition centres and they are also active in social activities," Son Young-rae, a senior health ministry official, told a briefing.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"We believe that the risk of infection will inevitably rise and the confirmed cases will continue to surge stemming from these teenagers."

Other nations including Britain, Israel and Germany have also seen the spread of COVID-19 among children fuelling a rise in overall cases and have expanded vaccination programmes for children to curb infections.

The United States is set to roll out Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) COVID-19 vaccines for children aged 5 to 11 as soon as Wednesday.

South Korea has not seen a noticeable increase in seriously ill cases among teens, with just one out of 378 severe COVID-19 patients being treated in hospitals. South Korea has also reported a relatively low mortality rate of 0.78%.

Vaccination for the 12-17 age group began in October with the Pfizer/BioNTech shots.

Latest comments

Wait over 90% of all population and yet they are reporting record cases? What does that say about the vaccine?
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.